Company Badge
USPTO Data Jan 1 1976 - Oct 20 2026
30 Patents
#210 in San Diego, CA
#2,682 in California
#11,279 in US
#21,912 in the World
Genelux Corporation
Forward Citations = 1,170
14 inventors:
San Diego, CA, United States of America
Genelux Corporation
Calculating rank
% Expired Patents = 40.0
CIPO Patents = 1
EPO Patents = 10
Forward Citations = 1,170
Loading Chart...
Loading Chart...
14 inventors (with patents filed for the assignee):
Aladar A Szalay (29 out of 44 patents)
Yong A Yu (25 out of 25 patents)
Qian Zhang (19 out of 61 patents)
4. Tatyana Timiryasova (13 out of 13 patents)
5. Nanhai G Chen (10 out of 15 patents)
6. Alexa Frentzen (4 out of 4 patents)
7. Shahrokh Shabahang (4 out of 5 patents)
8. Jochen Harald Stritzker (4 out of 4 patents)
9. Joseph Cappello (2 out of 26 patents)
10. Phil Hill (2 out of 2 patents)
11. Boris Minev (1 out of 10 patents)
12. Richard J Aguilar (1 out of 1 patent)
13. Jochen Stritzker (1 out of 3 patents)
14. Michael Hess (1 out of 1 patent)
15. Yuman Fong (4 patents)
Core Competencies:
Oncolytic Viruses
Vaccinia Virus
Bioreactor Production
Diagnostic Methods
Therapeutic Methods
Microorganisms
Tumor Imaging
Virus Infectivity
Light Emitting Cells
Bacterial Detection
Disease Treatment
Inflamed Tissue
30 patents:
1. 12338464 - Clonal strains of attenuated vaccinia viruses and methods of use thereof (2025-06-24),
2. 11149254 - Clonal strains of attenuated vaccinia viruses and methods of use thereof (2021-10-19),
6. 10238700 - Oncolytic virus adjunct therapy with agents that increase virus infectivity (2019-03-26),
7. 9944903 - Modified vaccinia virus strains for use in diagnostic and therapeutic methods (2018-04-17),
9. 9005602 - Modified vaccinia virus strains for use in diagnostic and therapeutic methods (2015-04-14),
Company Overview
Genelux Corporation is a biotechnology company based in San Diego, California, specializing in the development of innovative oncolytic virus therapies for cancer treatment. The company focuses on harnessing the power of genetically engineered viruses to selectively target and destroy cancer cells while sparing healthy tissue. With a commitment to advancing cancer therapeutics, Genelux is at the forefront of research in viral immunotherapy, aiming to improve patient outcomes through its cutting-edge technology and scientific expertise.
Profile summary synthesized from public USPTO records and patent filings.
IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Genelux Corporation. Retrieved from https://idiyas.com/company/genelux
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
1 patent (CIPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
10 patents (EPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]